The neuroprotective effect of PACAP, VIP, and derivatives in brain ischemia;Działanie neuroprotekcyjne PACAP, VIP oraz pochodnych w niedokrwieniu mózgu

Postepy Higieny i Medycyny Doswiadczalnej

Volumn 62, Issue , 2008, Pages 478-489

  Jóźwiak Bębenista, Marta ^a   Bednarek, Katarzyna ^a   Nowak, Jerzy Z ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Activity dependent neuroprotective protein, ADNP; Activity dependent neurotrophic factor, ADNF; Ischemia; Pituitary adenylate cyclase activating polypeptide, PACAP; Stroke; Vasoactive intestinal peptide, VIP

Indexed keywords

ADCYAP1 PROTEIN, HUMAN; ADNF PROTEIN, HUMAN; ANTIINFLAMMATORY AGENT; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; NERVE PROTEIN; NEUROPROTECTIVE AGENT; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE;

ADULT; BRAIN ISCHEMIA; CENTRAL NERVOUS SYSTEM; DRUG EFFECT; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; PATHOPHYSIOLOGY; REVIEW;

ADULT; ANTI-INFLAMMATORY AGENTS; BRAIN ISCHEMIA; CENTRAL NERVOUS SYSTEM; GENE EXPRESSION REGULATION; HUMANS; NERVE TISSUE PROTEINS; NEUROPROTECTIVE AGENTS; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; VASOACTIVE INTESTINAL PEPTIDE;

EID: 58149401953     PISSN: 00325449     EISSN: 17322693     Source Type: Journal    
DOI: None     Document Type: Article

References (129)

1. Arimura A.: Perspectives on pituitary adenylate cyclase activating polypeptide (PACAP) in the neuroendocrine, endocrine, and nervous systems. Jpn. J. Physiol., 1998; 48: 301-331
2. Ashur-Fabian O., Segal-Ruder Y., Skutelsky E., Brenneman D.E., Steingart R.A., Giladi E., Gozes I.: The neuroprotective peptide NAP inhibits the aggregation of the α-amyloid peptide. Peptides, 2003; 24: 1413-1423
3. Astrup J., Siesjo B.K., Symon L.: Threshold in cerebral ischemia-The ischemic penumbra. Stroke, 1981; 12: 723-725
4. Aubert N., Basille M., Falluel-Morel A., Vaudry D., Fisch C., de Jouffrey S., Le Bigot J.F., Fournier A., Vaudry H., Gonzales B.J.: PACAP protects granule cells against apoptosis induced by hypoxia in monkey cerebellum slices. Regul. Pept., 2005; 130: 156
5. Aubert N., Falluel-Morel A., Vaudry D., Fisch C.,de Jouffrey S., Le Bigot J.F., Vaudry H., Fournier A., Gonzales B.J.: PACAP and C2-ceramide generate different AP1 complexes through a MAP-kinasedependent pathway and differently regulate Bcl2 expression in rat cerebellar granule neurons. Regul. Pept., 2005; 130: 156
6. Banks W.A., Kastin A.J., Komaki G., Arimura A.: Passage of pituitary adenylate cyclase activating polypeptide 1-27 and pituitary adenylate cyclase activating polypeptide 1-38 across the blood-brain barrier. J. Pharmacol. Exp. Ther., 1993; 267: 690-696
7. Bar-Joseph A., Berkovitch Y., Adamchik J., Biegon A.: Neuroprotective activity of HU-211, a novel NMDA antagonist, in global ischemia in gerbils. Mol. Chem. Neuropathol., 1994; 23: 125-135
8. Bass E.: Cardiopulmonary arrest. Pathophysiology and neurologic complications. Ann. Intern. Med., 1985; 103: 920-927
9. Bassan M., Zamostiano R., Davidson A., Pinhasov A., Giladi E., Perl O., Bassan H., Blat C., Gibney G., Glazner G., Brenneman D.E., Gozes I.: Complete sequence of a novel protein containing femtomolar-activity-dependent neuroprotective peptide. J. Neurochem., 1999; 72: 1283-1293
10. Beck T., Lindholm D., Castrén E., Wree A.: Brain-derived neurotrophic factor protects against ischemic cell damage in rat hippocampus. J. Cereb. Blood Flow Metab., 1994; 14: 689-692
11. Bhave S.V., Hoffman P.L.: Phosphatidylinositol 3'-OH kinase and protein kinase A pathways mediate the anti-apoptotic effect of pituitary adenylyl cyclase-activating polypeptide in cultured cerebellar granule neurons: modulation by ethanol. J. Neurochem., 2004; 88: 359-369
12. Botia B., Basille M., Allais A., Raoult E., Falluel-Morel A., Galas L., Jolivel V., Wurtz O., Komuro H., Fournier A., Vaudry H., Burel D., Gonzales B.J., Vaudry D.: Neurotrophic effects of PACAP in the cerebellar cortex. Peptides, 2007; 28: 1746-1752
13. Brenneman D.E.: Neuroprotection: A comparative view of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Peptides, 2007; 28: 1720-1726
14. Brenneman D.E., Eiden L.E.: Vasoactive intestinal peptide and electrical activity influence neuronal survival. Proc. Natl. Acad. Sci. USA, 1986; 83: 1159-1162
15. Brenneman D.E., Hauser J., Neale E., Rubinraut S., Fridkin M., Davidson A., Gozes I.: Activity-dependent neurotrophic factor: structure-activity relationships of femtomolar-acting peptides. J. Pharmacol. Exp. Ther., 1998; 285: 619-627
16. Brenneman D.E., Hauser J., Phillips T.M., Davidson A., Bassan M., Gozes I.: Vasoactive intestinal peptide. Link between electrical activity and glia-mediated neurotrophism. Ann. NY Acad. Sci., 1999; 897: 17-26
17. Brenneman D.E., Hauser J., Spong C.Y., Phillips T.M.: Chemokines released from astroglia by vasoactive intestinal peptide. Mechanism of neuroprotection from HIV envelope protein toxicity. Ann. NY Acad. Sci., 2000; 921: 109-114
18. Brenneman D.E., Hauser J.M., Spong C., Phillips T.M.: Chemokine release is associated with the protective action of PACAP-38 against HIV envelope protein neurotoxicity. Neuropeptides, 2002; 36: 271-280
19. Brenneman D.E., Phillips T.M., Hauser J., Hill J.M., Spong C.Y., Gozes I.: Complex array of cytokines released by vasoactive intestinal peptide. Neuropeptides, 2003; 37: 111-119
20. Brenneman D.E., Spong C.Y., Gozes I.: Protective peptides derived from novel glial proteins. Biochem. Soc. Transac., 2000; 28: 452-455
21. Brenneman D.E., Westbrook G.L., Fitzgerald S.P., Ennist D.L., Elkins K.L., Ruff M.R., Pert C.B.: Neuronal cell killing by the envelope protein of HIV and its prevention by vasoactive intestinal peptide. Nature 1988; 335: 639-642
22. Chen Y., Samal B., Hamelink C.R., Xiang C.C., Chen Y., Chen M., Vaudry D., Brownstein M.J., Hallenbeck J.M., Eiden L.E.: Neuroprotection by endogenous and exogenous PACAP following stroke. Regul. Pept., 2006; 137: 4-19
23. Clarkson A.N., Sutherland B.A., Appleton I.: The biology and pathology of hypoxia-ischemia: an update. Arch. Immunol. Ther. Exp., 2005; 53: 213-225
24. Dejda A., Sokoowska P., Nowak J.Z.: Neuroprotective potential of three neuropeptides PACAP, VIP and PHI. Pharmacol. Rep., 2005; 57: 307-320
25. Delgado M.: Inhibition of interferon (IFN) g-induced Jak-STAT1 activation in microglia by vasoactive intestinal peptide: inhibitory effect on CD40, IFN-induced protein-10, and inducible nitric-oxide synthase expression. J. Biol. Chem., 2003; 278: 27620-27629
26. Delgado M., Ganea D.: Inhibition of endotoxin-induced macrophage chemokine production by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in vitro and in vivo. J. Immunol., 2001; 167: 966-975
27. Delgado M., Ganea D.: Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson's disease by blocking microglial activation. FASEB J., 2003; 17: 944-946
28. Delgado M., Ganea D.: Vasoactive intestinal peptide prevents activated microglia-induced neurodegeneration under inflammatory conditions: potential therapeutic role in brain trauma. FASEB J., 2003; 17: 1922-1924
29. Delgado M., Jonakait G.M., Ganea D.: Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit chemokine production in activated microglia. Glia, 2002; 39: 148-161
30. Delgado M., Leceta J., Ganea D.: Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the production of inflammatory mediators by activated microglia. J. Leukoc. Biol., 2003; 73: 155-164
31. De Simoni M.G., Milia P., Barba M., De Luigi A., Parnetti L., Gallai V.: The inflammatory response in cerebral ischemia: focus on cytokines in stroke patients. Clin. Exp. Hypertens., 2002; 24: 535-542
32. Dohi K., Mizushima H., Nakajo S., Ohtaki H., Matsunaga S., Aruga T., Shioda S.: Pituitary adenylate cyclase-activating polypeptide (PACAP) prevents hippocampal neurons from apoptosis by inhibiting JNK/SAPK and p38 signal transduction pathways. Regul. Pept., 2002; 109: 83-88
33. Domañska-Janik K., Bong P.: Niedokrwienie OUN-molekularne mechanizmy mierci neuronów. Farmacja Polska, 2000; 56: 488-496
34. Dringen R., Schmoll D., Cesar M., Hamprecht B.: Incorporation of radioactivity from C14 lactate into the glycogen of cultured mouse astroglial cells. Evidence for gluconeogenesis in brain cells. Biol. Chem. Hoppe Seyler, 1993; 374: 343-347
35. Fahrenkrug J., Hannibal J., Tams J., Georg B.: Immunohistochemical localization of the VIP1 receptor (VPAC1R) in rat cerebral blood vessels: relation to PACAP and VIP containing nerves. J. Cereb. Blood Flow Metab., 2000; 20: 1205-1214
36. Foulkes M.A., Wolf P.A., Price T.R., Mohr J.P., Hier D.B.: The Stroke Data Bank: design, methods, and baseline characteristics. Stroke, 1988; 19: 547-554
37. Frechilla D., Garcia-Osta A., Palacios S., Cenarruzabeitia E., Del Rio J.: BDNF mediates the neuroprotective effect of PACAP-38 on rat cortical neurons. Neuroreport, 2001; 12: 919-923
38. Fujikawa K., Nagayama T., Inoue K., Minamino N., Kangawa K., Nitro M., Miyata A.: C-type natriuretic peptide (CNP) is specifically induced by PACAP and involved in the neuroprotective effects of PACAP. Regul. Pept., 2005; 130: 161
39. Gabryel B., Trzeciak H.I.: Role of astrocytes in pathogenesis of ischemic brain injury. Neurotoxicity Res. 2001; 3: 205-221
40. Gibney G., Glazner G., Brenneman D.E., Gozes I.: Complete sequence of novel protein containing a femtomolar-activity-dependent neuroprotective peptide. J. Neurochem., 1999; 72: 1283-1293
41. Gillardon F., Hata R., Hossmann K.A.: Delayed up-regulation of Zac1 and PACAP type I receptor after transient focal cerebral ischemia in mice. Brain Res. Mol. Brain Res., 1998; 61: 207-210
42. González-Scarano F., Baltuch G.: Microglia as mediators of inflammatory and degenerative diseases. Annu. Rev. Neurosci., 1999; 22: 219-240
43. Gottschall P.E., Tatsuno I., Arimura A.: Regulation of interleukin-6 (IL-6) secretion in primary cultured rat astrocytes: synergism of interleukin-1 (IL-1) and pituitary adenylate cyclase activating polypeptide (PACAP). Brain Res., 1994; 637: 197-203
44. Gozes I., Bachar M., Bardea A., Davidson A., Rubinraut S., Fridkin M., Giladi E.: Protection against developmental retardation in apolipoprotein E-deficient mice by a fatty neuropeptide: implications for early treatment of Alzheimer's disease. J. Neurobiol., 1997; 33: 329-342
45. Gozes I., Bardea A., Reshef A., Zamostiano R., Zhukovsky S., Rubinraut S., Fridkin M., Brenneman D.E.: Neuroprotective strategy for Alzheimer disease: intranasal administration of a fatty neuropeptide. Proc. Natl. Acad. Sci. USA, 1996; 93: 427-432
46. Gozes I., Brenneman D.E.: VIP: molecular biology and neurobiological function. Mol. Neurobiol., 1989; 3: 201-236
47. Gozes I., Divinski I.: NAP, a neuroprotective drug candidate in clinical trials, stimulates microtubule assembly in the living cell. Curr. Alzheimer Res., 2007; 4: 507-509
48. Gozes I., Divinski I., Pilzer I., Fridkin M., Brenneman D.E., Spier A.D.: From vasoactive intestinal peptide (VIP) through activity-dependent neuroprotective protein (ADNP) to NAP: A view of neuroprotection and cell division. J. Mol. Neurosci., 2003; 20: 315-322
49. Gozes I., Giladi E., Pinhasov A., Bardea A., Brenneman D.E.: Activitydependent neurotrophic factor: intranasal administration of femtomolar-acting peptides improve performance in a water maze. J. Pharmacol. Exp. Ther., 2000; 293: 1091-1098
50. Gozes I., Lilling G., Glazer R., Ticher A., Ashkenazi I.E., Davidson A., Rubinraut S., Fridkin M., Brenneman D.E.: Superactive lipophilic peptides discriminate multiple vasoactive intestinal peptide receptors. J. Pharmacol. Exp. Ther., 1995; 273: 161-167
51. Gozes I., Zamostiano R., Pinhasov A., Bassan M., Giladi E., Steingart R.A., Brenneman D.E.: A novel VIP responsive gene. Activity dependent neuroprotective protein. Ann. NY Acad. Sci., 2000; 921: 115-118
52. Green A.R.: Pharmacological approaches to acute ischaemic stroke: reperfusion certainly, neuroprotection possibly. Br. J. Pharmacol., 2008; 153(Suppl.1): S325-S338
53. Haydon P.G.: Neuroglial networks: neurons and glia talk to each other. Curr. Biol., 2000; 10: R712-R714
54. Huang R., Hertz L.: Effect of anoxia on glutamate formation from glutamine in cultured neurons: dependence on neuronal subtype. Brain Res., 1994; 660: 129-137
55. Jaworski D.M.: Expression of pituitary adenylate cyclase-activating polypeptide (PACAP) and the PACAP-selective receptor in cultured rat astrocytes, human brain tumors, and in response to acute intracranial injury. Cell Tissue Res., 2000; 300: 219-230
56. Kaminska B., Gaweda-Walerych K., Zawadzka M.: Molecular mechanisms of neuroprotective action of immunosuppressants-facts and hypotheses. J. Cell. Mol. Med., 2004; 8: 45-58
57. Katchanov J., Waeber C., Gertz K., Gietz A., Winter B., Brück W., Dirnagl U., Veh R.W., Endres M.: Selective neuronal vulnerability following mild focal brain ischemia in the mouse. Brain Pathol., 2003; 13: 452-264
58. Kim W.K., Ganea D., Jonakait G.M.: Inhibition of microglial CD40 expression by pituitary adenylate cyclase-activating polypeptide is mediated by interleukin-10. J. Neuroimmunol., 2002; 126: 16-24
59. Kumral A., Yesilirmak D.C., Sonmez U., Baskin H., Tugyan K., Yilmaz O., Genc S., Gokmen N., Genc K., Duman N., Ozkan H.: Neuroprotective effect of the peptides ADNF-9 and NAP on hypoxic-ischemic brain injury in neonatal rats. Brain Res., 2006; 1115: 169-178
60. Lee T.J., Saito A., Berezin I.: Vasoactive intestinal polypeptide-like substance: The potential transmitter for cerebral vasodilation. Science, 1984; 224: 898-901
61. Leker R.R., Teichner A., Grigoriadis N., Ovadia H., Brenneman D.E., Fridkin M., Giladi E., Romano J., Gozes I.: NAP, a femtomolar-acting peptide, protects the brain against ischemic injury by reducing apoptotic death. Stroke, 2002; 33: 1085-1092
62. Li M., David C., Kikuta T., Somogyvári-Vigh A., Arimura A.: Signaling cascades involved in neuroprotection by subpicomolar pituitary adenylate cyclase-activating polypeptide 38. J. Mol. Neurosci., 2005; 27: 91-105
63. Linnik M.D., Zobrist R.H., Hatfield M.D.: Evidence supporting a role for programmed cell death in focal cerebral ischemia in rats. Stroke, 1993; 24: 2002-2008
64. Litwin T., Kobayashi A., Skowroñska M., Czonkowska A.: Thrombolysis in acute ischaemic stroke within 3 hours of symptom onset: A report of the first 100 cases. Neurol. Neurochir. Pol., 2008; 42: 1-5
65. Luna-Medina R., Cortes-Canteli M., Alonso M., Santos A., Martinez A., Perez-Castillo A.: Regulation of inflammatory response in neural cells in vitro by thiadiazolidinones derivatives through peroxisome proliferator-activated receptor g activation. J. Biol. Chem., 2005; 280: 21453-21462
66. Markiewicz I., Lukomska B.: The role of astrocytes in the physiology and pathology of the central nervous system. Acta Neurobiol. Exp., 2006; 66: 343-358
67. Martin L.J., Al.-Abdulla N.A., Brambrink A.M., Kirsch J.R., Sieber F.E., Portera-Cailliau C.: Neurodegeneration in excitotoxicity, global cerebral ischemia, and target deprivation: A perspective on the contributions of apoptosis and necrosis. Brain Res. Bull., 1998; 46: 281-309
68. Masmoudi-Kouki O., Gandolfo P., Castel H., Leprince J., Fournier A., Dejda A., Vaudry H., Tonon M.C.: Role of PACAP and VIP in astroglial functions. Peptides, 2007; 28: 1753-1760
69. Matsuoka Y., Gray A.J., Hirata-Fukae C., Minami S.S., Waterhouse E.G., Mattson M.P., LaFerla F.M., Gozes I., Aisen P.S.: Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation In a transgenic mouse model of Alzheimer's disease at early pathological stage. J. Mol. Neurosci., 2007; 31: 165-170
70. McCulloch J.: Glutamate receptor antagonists in cerebral ischaemia. J. Neural Transm. Suppl., 1994; 43: 71-79
71. Mehta S.L., Manhas N., Raghubir R.: Molecular targets in cerebral ischemia for developing novel therapeutics. Brain Res. Rev., 2007; 54: 34-66
72. Miller A., Glass-Marmor L., Abraham M., Grossman I., Shapiro S., Galboiz Y.: Bio-markers of disease activity and response to therapy in multiple sclerosis. Clin. Neurol. Neurosurg., 2004; 106: 249-254
73. Minami M., Katayama T., Satoh M.: Brain cytokines and chemokines: roles in ischemic injury and pain. J. Pharmacol. Sci., 2006; 100: 461-470
74. Minghetti L., Levi G.: Microglia as effector cells in brain damage and repair: focus on prostanoids and nitric oxide. Prog. Neurobiol., 1998; 54: 99-125
75. Morio H., Tatsuno I., Hirai A., Tamura Y., Saito Y.: Pituitary adenylate-cyclase activating polypeptide protects rat-cultured cortical neurons from glutamate-induced cytotoxicity. Brain Res., 1996; 741: 82-88
76. Muller J.M., Debaigt C., Goursaud S., Montoni A., Pineau N., Meunier A.C., Janet T.: Unconventional binding sites and receptors for VIP and related peptides PACAP and PHI/PHM: an update. Peptides, 2007; 28: 1655-1666
77. Nakayama T., Momoki-Soga T., Inoue N.: Astrocyte-derived factors instruct differentiation of embryonic stem cells into neurons. Neurosci. Res., 2003; 46: 241-249
78. Nedergaard M.: Neuronal injury in the infarct border: A neuropathological study in the rat. Acta Neuropathol., 1987; 73: 267-274
79. Nedergaard M., Dirnagl U.: Role of glial cells in cerebral ischemia. Glia, 2005; 50: 281-286
80. Nedergaard M., Ransom B., Goldman S.A.: New roles for astrocytes: redefining the functional architecture of the brain. Trends Neurosci., 2003; 26: 523-530
81. Nowak J.Z., JóYwiak-Bêbenista M., Bednarek K.: Effects of PACAP and VIP on cyclic AMP formation in rat neuronal and astrocyte cultures under normoxic and hypoxic condition. Peptides, 2007; 28: 1706-1712
82. Nowak J.Z., Zawilska J.B.: PACAP in avians: origin, occurrence, and receptors-pharmacological and functional considerations. Curr. Pharm. Des., 2003; 9: 467-481
83. Offen D., Sherki Y., Melamed E., Fridkin M., Brenneman D.E., Gozes I.: Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson's disease. Brain Res., 2000; 854: 257-262
84. Ohtaki H., Nakamachi T., Dohi K., Aizawa Y., Takaki A., Hodoyama K., Yofu S., Hashimoto H., Shintani N., Baba A., Kopf M., Iwakura Y., Matsuda K., Arimura A., Shioda S.: Pituitary adenylate cyclaseactivating polypeptide (PACAP) decreases ischemic neuronal cell death in association with IL-6. Proc. Natl. Acad. Sci. USA, 2006; 103: 7488-7493
85. Ohtaki H., Nakamachi T., Dohi K., Hodoyama K., Hashimoto H., Shintani N., Baba A., Arimura A., Shioda S.: Neuroprotective mechanism of PACAP after focal ischemia in mouse. Regul. Pept., 2005; 130: 149
86. Onoue S., Endo K., Ohshima K., Yajima T., Kashimoto K.: The neuropeptide PACAP attenuates β-amyloid (1-42)-induced toxicity in PC12 cells. Peptides, 2002; 23: 1471-1478
87. Onoue S., Ohshima K., Endo K., Yajima T., Kashimoto K.: PACAP protects neuronal PC12 cells from the cytotoxicity of human prion protein fragment 106-126. FEBS Lett., 2002; 522: 65-70
88. Pilzer I., Gozes I.: VIP provides cellular protection through a specific splice variant of the PACAP receptor: A new neuroprotection target. Peptides, 2006; 27: 2867-2876
89. Postêpowanie w ostrym udarze niedokrwiennym mózgu. Raport zespou ekspertów Narodowego Programu Profilaktyki i Leczenia Udaru Mózgu. Neurol. Neurochir. Pol., 1999; Supl. 4
90. Prusiñski A., Doma T.M., Kozubski W., Szczudlik A.: Niedokrwienne udary mózgu. a-Medica Press, Bielsko-Biaa 1999
91. Reglodi D., Lubics A., Tamás A., Szalomtay L., Lengvári I.: Pituitary adenylate cyclase activating polypeptide protects dopaminergic neurons and improves behavioral deficits in a rat model of Parkinson's disease. Behav. Brain Res., 2004; 151: 303-312
92. Reglodi D., Somogyvári-Vigh A., Vigh S., Kozicz T., Arimura A.: Delayed systemic administration of PACAP38 is neuroprotective in transient middle cerebral artery occlusion in the rat. Stroke, 2000; 31: 1411-1417
93. Reglodi D., Tamás A., Somogyvári-Vigh A., Szántó Z., Kertes E., Lénárd L., Arimura A., Lengvári I.: Effects of pretreament with PACAP on the infarct size and functional outcome in rat permanent focal cerebral ischemia. Peptides, 2002; 23: 2227-2234
94. Ridet J.L., Malhotra S.K., Privat A., Gage F.H.: Reactive astrocytes: cellular and molecular cues to biological function. Trends Neurosci., 1997; 20: 570-577
95. Said S.I., Dickman K., Dey R.D., Bandyopadhyay A., De Stefanis P., Raza S., Pakbaz H., Berisha H.I.: Glutamate toxicity in the lung and neuronal cells: prevention or attenuation by VIP and PACAP. Ann. NY Acad. Sci., 1998; 865: 226-237
96. Schmalenbach C., Mûller H.W.: Astroglia-neuron interactions that promote long-term neuronal survival. J. Chem. Neuroanat., 1993; 6: 229-237
97. Schmoll D., Führmann E., Gebhardt R., Hamprecht B.: Significant amounts of glycogen are synthesized from 3-carbon compounds in astroglial primary cultures from mice with participation of the mitochondrial phosphoenolpyruvate carboxykinase isoenzyme. Eur. J. Biochem. 1995; 227: 308-315
98. Shintani N., Suetake S., Hashimoto H., Koga K., Kasai A., Kawaguchi C., Morita Y., Hirose M., Sakai Y., Tomimoto S., Matsuda T., Baba A.: Neuroprotective action of endogenous PACAP in cultured rat cortical neurons. Regul. Pept., 2005; 126: 123-128
99. Shioda S., Ohtaki H., Nakamachi T., Dohi K., Watanabe J., Nakajo S., Arata S., Kitamura S., Okuda H., Takenoya F., Kitamura Y.: Pleiotropic functions of PACAP in the CNS: neuroprotection and neurodevelopment. Ann. N Y Acad. Sci., 2006; 1070: 550-560
100. Shioda S., Ozawa H., Dohi K., Mizushima H., Matsumoto K., Nakajo S., Takaki A., Zhou C.J., Nakai Y., Arimura A.: PACAP protects hippocampal neurons against apoptosis: involvement of JNK/SAPK signaling pathway. Ann. NY Acad. Sci., 1998; 865: 111-117
101. Sigalov E., Fridkin M., Brenneman D.E., Gozes I.: VIP-related protection against lodoacetate toxicity in pheochromocytoma (PC12) cells: A model for ischemic/hypoxic injury. J. Mol. Neurosci., 2000; 15: 147-154
102. Skoglösa Y., Lewén A., Takei N., Hillered L., Lindholm D.: Regulation of pituitary adenylate cyclase activating polypeptide and its receptor type 1 after traumatic brain injury: comparison with brain-derived neurotrophic factor and the induction of neuronal cell death. Neuroscience, 1999; 90: 235-247
103. Sokoowska P., Dejda A., Nowak J.Z.: Neuroprotekcyjna rola peptydów PACAP, VIP orza PHI w orodkowym ukadzie nerwowym. Post. Hig. Med. Dow., 2004; 58: 416-427
104. Somogyvári-Vigh A., Reglodi D.: Pituitary adenylate cyclase activating polypeptide: A potential neuroprotective peptide. Curr. Pharm. Des., 2004; 10: 2861-2889
105. Somogyvári-Vigh A., Svoboda-Teet J., Vigh S., Arimura A.: Is an intravenous bolus injection required prior to initiating slow intravenous infusion of PACAP38 for prevention of neuronal death induced by global ischemia? The possible presence of a binding protein for PACAP38 in blood. Ann. NY Acad. Sci., 1998; 865: 595-600
106. Steingart R.A., Solomon B., Brenneman D.E., Fridkin M., Gozes I.: VIP and peptides related to activity-dependent neurotrophic factor protect PC12 cells against oxidative stress. J. Mol. Neurosci., 2000; 15: 137-145
107. Stoll G.: Inflammatory cytokines in the nervous system: multifunctional mediators in autoimmunity and cerebral ischemia. Rev. Neurol., 2002; 158: 887-891
108. Strosznajder J.B., Czernicki Z.: Mózg a niedokrwienie. Platan, Kraków, 2005
109. Stumm R., Kolodziej A., Prinz V., Endres M., Wu D.F., Höllt V.: Pituitary adenylate cyclase-activating polypeptide is up-regulated in cortical pyramidal cells after focal ischemia and protects neurons from mild hypoxic/ischemic damage. J. Neurochem., 2007; 103: 1666-1681
110. Suk K., Park J.H., Lee W.H.: Neuropeptide PACAP inhibits hypoxic activation of brain microglia: A protective mechanism against microglial neurotoxicity in ischemia. Brain Res., 2004; 1026: 151-156
111. Suzuki R., Arata S., Nakajo S., Ikenaka K., Kikuyama S., Shioda S.: Expression of the receptor for pituitary adenylate cyclase-activating polypeptide (PAC1-R) in reactive astrocytes. Brain Res. Mol. Brain Res., 2003; 115: 10-20
112. Szczudlik A.: Neuroprotekcja jako kierunek leczenia niedokrwienia mózgu. XX Zimowa Szkoa Instytutu Farmakologii PAN, 2003: 99-105
113. Takeda N., Murozono M., Watanabe S., Isshiki A., Watanabe Y.: Neuroprotective effects of novel derivatives of vasoactive intestinal peptide and pituitary adenylate cyclase-activating peptide in two brain ischemic models on mice. Masui, 2005; 54: 240-248
114. Trendelenburg G., Dirnagl U.: Neuroprotective role of astrocytes in cerebral ischemia: focus on ischemic preconditioning. Glia, 2005; 50: 307-320
115. Trendelenburg G., Prass K., Priller J., Kapinya K., Polley A., Muselmann C., Ruscher K., Kannbley U., Schmitt A.O., Castell S., Wiegand F., Meisel A., Rosenthal A., Dirnagl U.: Serial analysis of gene expression identifies metallothionein-II as major neuroprotective gene in mouse focal cerebral ischemia. J. Neurosci., 2002; 22: 5879-5888
116. Uchida D., Arimura A., Somogyváari-Vigh A., Shioda S., Banks W.A.: Prevention of ischemia-induced death of hippocampal neurons by pituitary adenylate cyclase activating polypeptide. Brain Res., 1996; 736: 280-286
117. Ullian E.M., Sapperstein S.K., Christopherson K.S., Barres B.A.: Control of synapse number by glia. Science, 2001; 291: 657-661
118. van Rossum D., Hanisch U.K.: Microglia. Metab. Brain Dis., 2004; 19: 393-411
119. Vaudry D., Falluel-Morel A., Basille M., Pamantung T.F., Fontaine M., Fournier A., Vaudry H., Gonzalez B.J.: Pituitary adenylate cyclase-activating polypeptide prevents C2-ceramide-induced apoptosis of cerebellar granule cells. J. Neurosci. Res., 2003; 72: 303-316
120. Vaudry D., Gonzalez B.J., Basille M., Anouar Y., Fournier A., Vaudry H.: Pituitary adenylate cyclase-activating polypeptide stimulates both c-fos gene expression and cell survival in rat cerebellar granule neurons through activation of the protein kinase A pathway. Neuroscience, 1998; 84: 801-812
121. Vaudry D., Gonzalez B.J., Basille M., Pamantung T.F., Fontaine M., Fournier A., Vaudry H.: The neuroprotective effect of pituitary adenylate cyclase activating polypeptide on cerebellar granule cells is mediated through inhibition of the CED3-related cysteine protease caspase-3/CPP32. Proc. Natl. Acad. Sci. USA, 2000; 97: 13390-13395
122. Vaudry D., Gonzalez B.J., Basille M., Yon L., Fournier A., Vaudry H.: Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. Pharmacol. Rev., 2000; 52: 269-324
123. Vaudry D., Pamantung T.F., Basille M., Rousselle C., Fournier A., Vaudry H., Beauvillain J.C., Gonzalez B.J.: PACAP protects cerebellar granule neurons against oxidative stress-induced apoptosis. Eur. J. Neurosci., 2002; 15: 1451-1460
124. Vaudry D., Rousselle C., Basille M., Falluel-Morel A., Pamantung T.F., Fontaine M., Fournier A., Vaudry H., Gonzales B.J.: Pituitary adenylate cyclase-activating polypeptide protects rat cerebellar granule neurons against ethanol-induced apoptotic cell death. Proc. Natl. Acad. Sci. USA, 2002; 99: 6398-6403
125. Villegas S.N., Poletta F.A., Carri N.G.: A reassessment based on novel data on the developing and mature central nervous system. Cell Biol. Int., 2003; 27: 599-609
126. Yang S.: Vasoactive intestinal peptide (VIP) concentration in ischemic rat brain microvessels. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. Acta Acad. Med. Sinicae, 1991; 13: 227-229
127. Zemlyak I., Furman S., Brenneman D.E., Gozes I.: A novel peptide prevents death in enriched neuronal cultures. Regul. Pept., 2000; 96: 39-43
128. Zhang Y.Z., Hannibal J., Zhao Q., Moller K., Danielsen N., Fahrenkrug J., Sundler F.: Pituitary adenylate cyclase activating peptide expression in the rat dorsal root ganglia: up-regulation after peripheral nerve injury. Neuroscience, 1996; 74: 1099-1110
129. Zusev M., Gozes I.: Differential regulation of activity-dependent neuroprotective protein in rat astrocytes by VIP and PACAP. Regul. Pept., 2004; 123: 33-41